Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04965090 · ClinicalTrials.gov registry record · Phase 2
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT04965090: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04965090 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04965090, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The researchers think that the study drugs, amivantamab and lazertinib, may be an effective treatment for people who have metastatic NSCLC with an EGFR mutation. Both drugs work to target cancer cells with an EGFR mutation, and this targeting action could stop or slow the growth of cancer cells. The researchers are doing this study to find out how well amivantamab and lazertinib work against metastatic NSCLC with an EGFR mutation.
Interventions
- DRUG Amivantamab
- DRUG Lazertinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2025-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04965090
The ClinicalTrials.gov registry entry for NCT04965090 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Amivantamab is the first listed.
NCT04965090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04965090 about?
NCT04965090 is a clinical study titled "A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)". The researchers think that the study drugs, amivantamab and lazertinib, may be an effective treatment for people who have metastatic NSCLC with an EGFR mutation. Both drugs work to target cancer cells with an EGFR mutation, and this targeting action could stop or slow the growth of cancer cells. The...
What is the current status of trial NCT04965090?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2021-09-30. Estimated completion is 2025-12-15.
What interventions are being tested in trial NCT04965090?
The interventions under investigation include: Amivantamab (DRUG), Lazertinib (DRUG).
Who is sponsoring clinical trial NCT04965090?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.